Publication: Effectiveness and safety of sodium–glucose co-transporter-2 inhibitors in Thai adults with type 2 diabetes mellitus: a real-world study
Issued Date
2020-01-01
Resource Type
ISSN
14734877
03007995
03007995
Other identifier(s)
2-s2.0-85089919246
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Current Medical Research and Opinion. (2020)
Suggested Citation
Chutintorn Sriphrapradang, Yotsapon Thewjitcharoen, Supawan Buranapin, Kittisak Sawanyawisuth, Nalin Yenseung, Wisawa Ubonchareon, Laddawan Limpijankit, Thep Himathongkam Effectiveness and safety of sodium–glucose co-transporter-2 inhibitors in Thai adults with type 2 diabetes mellitus: a real-world study. Current Medical Research and Opinion. (2020). doi:10.1080/03007995.2020.1808454 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/59305
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Effectiveness and safety of sodium–glucose co-transporter-2 inhibitors in Thai adults with type 2 diabetes mellitus: a real-world study
Abstract
© 2020 Informa UK Limited, trading as Taylor & Francis Group. Background: Sodium–glucose co-transporter-2 inhibitors (SGLT2is) are widely used to improve both glycemic control and cardio-renal outcomes. We aim to evaluate the real-life clinical effectiveness, safety and outcomes of SGLT2is in Thai adults with type 2 diabetes mellitus (T2DM). Methods: This was a retrospective study involving adults with T2DM who were treated with SGLT2is for ≥3 months. Results: Among 1159 participants (women 52.6%; age: 61.1 ± 10.9 years; body mass index: 28.7 ± 5.2 kg/m2), 65.1%, 34.3% and 0.6% received dapagliflozin, empagliflozin and canagliflozin, respectively. Median SGLT2i treatment duration was 15 (IQR, 8–23) months. Of the patients, 16.5%, 6.4%, 4.9% and 1.6% had pre-existing coronary artery disease, stroke, heart failure and peripheral arterial disease, respectively. Mean HbA1c decreased by 0.7% (95% CI, −1.0 to −0.4) from a baseline of 8.3 ± 1.5%. At 24 months, body weight, and systolic and diastolic blood pressure decreased significantly from the baseline average of 2.5 kg, 3.5 mmHg and 2.4 mmHg, respectively. The median decline in eGFR was −1.3 ml/min/1.73 m2/year. The incidences of pollakiuria, genital tract infection, urinary tract infection and hypoglycemia were 7.2%, 2.8%, 2.2% and 0.9%, respectively. No participants developed diabetic ketoacidosis during the observation period. Conclusions: SGLT2is improved cardiometabolic parameters in Thai adults, clinically confirming findings in controlled trials.